An analysis of the human immunodeficiency virus (HIV) epidemic’s trajectory with priority-setting taking into account HIV-associated comorbidities for each time period was performed. A classification of comorbid diseases and conditions in HIV infection by cause and setting of their occurrence is presented. Opportunistic infections and secondary diseases that remain some of the leading causes of severe complications and mortality are characterized. The difficulty of the development of immune reconstitution inflammatory syndrome against the background of late diagnosis of HIV infection and initiation of antiretroviral therapy is highlighted.
Background Russia has a high prevalence of human immunodeficiency virus (HIV) infections. In 2018, over one million persons were living with HIV (PLWH); over a third were women. A high proportion of HIV-infected women are co-infected with hepatitis C virus (HCV), and many consume alcohol, which adversely affects HIV and HCV treatment and prognosis. Despite the triple epidemics of alcohol use, HIV and HCV, and the need for interventions to reduce alcohol use among HIV/HCV co-infected women, evidence-based alcohol reduction interventions for this vulnerable population are limited. To address this gap, we developed a clinical trial to evaluate the efficacy of a computer-based intervention to reduce alcohol consumption among HIV/HCV co-infected women in clinical care. Methods In this two-arm parallel randomized controlled trial, we propose to evaluate the efficacy of a culturally adapted alcohol reduction intervention delivered via a computer for HIV/HCV co-infected Russian women. The study population consists of women 21–45 years old with confirmed HIV/HCV co-infection who currently use alcohol. Intervention efficacy is assessed by a novel alcohol biomarker, ethyl glucuronide (EtG), and biomarkers of HIV and HCV disease progression. Women are randomized to trial conditions in a 1:1 allocation ratio, using a computer-generated algorithm to develop the assignment sequence and concealment of allocation techniques to minimize assignment bias. Women are randomized to either (1) the computer-based alcohol reduction intervention or (2) the standard-of-care control condition. We will use an intent-to-treat analysis and logistic and linear generalized estimating equations to evaluate intervention efficacy, relative to the standard of care, in enhancing the proportion of women with a laboratory-confirmed negative EtG at each research study visit over the 9-month follow-up period. Additional analyses will evaluate intervention effects on HIV (viral load and CD4+ levels) and HCV markers of disease progression (FibroScan). Discussion The proposed trial design and analysis provides an appropriate conceptual and methodological framework to assess the efficacy of the computer-based intervention. We propose to recruit 200 participants. The intervention, if efficacious, may be an efficient and cost-effective alcohol reduction strategy that is scalable and can be readily disseminated and integrated into clinical care in Russia to reduce women’s alcohol consumption and enhance HIV/HCV prognosis. Trial registration ClinicalTrials.gov NCT03362476. Registered on 5 December 2017
The purpose statement is to assess the course of the COVID-19 pandemic and its impact on the epidemics of HIV infection, viral hepatitis C (HCV), tuberculosis, influenza, and acute respiratory infections in the North-Western Federal District (NWFD) of the Russian Federation during two years of spreading COVID-19 from the standpoint of the possible formation of syndemia or interference between pathogens.Materials and methods. Data collection on HIV infection and HCV was carried out by Pasteur Research Institute of Epidemiology and Microbiology at St. Petersburg Medical Information and Analytical Center using data from federal state statistical observation forms and our own research materials. The indicators of excess mortality from all causes for 2020 in the Northwestern Federal District (NWFD) and in the Russian Federation were analyzed according to the data of the Federal State Statistics Service (ROSSTAT). The results of epidemiological surveillance of HIV infection, viral hepatitis C (HCV), and tuberculosis in the Russian Federation and in the NWED in 2020 and 2021 in comparison with previous years are summarized. Studies of influenza and SARS were carried out by Smorodintsev Research Institute of Influenza and Gamaleya National Research Center for Epidemiology and Microbiology in cooperation with regional support bases. PCR detection of ARVI pathogens was carried out.Results and discussion. An analysis of epidemic indicators across the territories of the Northwestern Federal District of the Russian Federation made it possible to identify the following features: heterogeneity of the incidence of COVID-19 in the population in terms of time and intensity; the prevalence of morbidity in the metropolis (St. Petersburg) and industrial northern regions (the republics of Karelia and Komi). In a comparative aspect, the NWFD belongs to regions with high morbidity and mortality in the Russian Federation. St. Petersburg (378 deaths per 100,000 people in 2021) ranks second after Moscow. In turn, the Vologda, Murmansk, and Arkhangelsk regions, as well as the Komi Republic are among the top ten of the most affected subjects of the Russian Federation in the country. In terms of mortality, St. Petersburg was significantly ahead of all other subjects of the Russian Federation and the national average, which had several probable reasons. The first and second years of the pandemic did not reveal significant changes in epidemic rates of morbidity and mortality from other socially significant infections — HIV, HCV, and tuberculosis at the population level characteristic interference of viruses, where SARS-CoV-2 took the place of interfering, and influenza and SARS pretending or interfering pathogens. It took several months until the beginning of winter 2020 to crowd out seasonal respiratory infections by SARS-CoV-2. Then SARS-CoV-2 tightly captured the epidemic space, leaving no room for traditional respiratory infections, which accounted for less than 5% in early 2022.Conclusion. The COVID-19 epidemic had pronounced developmental features with higher morbidity and mortality in the metropolis and other industrial centers. The pandemic did not significantly affect the patterns of the epidemic course of HIV, HCV, and tuberculosis, which rejected the presence of a syndemic between these pathogens. Interference with respiratory infections — influenza and SARS — was revealed with a clear predominance of SARS-CoV-2.
Background: Russia has a high prevalence of HIV. In 2018, over one million persons were living with HIV (PLWH); over a third were women. A high proportion of HIV-infected women are co-infected with Hepatitis C virus (HCV); and many consume alcohol, which adversely affects HIV and HCV treatment and prognosis. In spite of the triple epidemics of alcohol use, HIV and HCV, and the need for interventions to reduce alcohol use among HIV/HCV co-infected women, evidence-based alcohol reduction interventions for this vulnerable population are limited. To address this gap, we developed a clinical trial to evaluate the efficacy of a computer-based intervention to reduce alcohol consumption among HIV/HCV co-infected women in clinical care. Methods: In this two-arm parallel randomized clinical trial, we propose to evaluate the efficacy of a culturally-adapted alcohol reduction intervention delivered via a computer for HIV/HCV co-infected Russian women. The study population consists of women 21-45 years old, with confirmed HIV/HCV co-infection who currently use alcohol. Intervention efficacy is assessed by a novel alcohol biomarker, ethyl glucuronide (EtG) and biomarkers of HIV and HCV disease progression. Women are randomized to trial conditions in a 1:1 allocation ratio, using a computer-generated algorithm to develop the assignment sequence, and concealment of allocation techniques to minimize assignment bias. Women are randomized to either: (1) the computer-based alcohol reduction intervention, or (2) the standard-of-care control condition. We will use an intent-to-treat analysis and logistic and linear generalized estimating equations to evaluate intervention efficacy, relative to the standard-of-care, in enhancing the proportion of women with a laboratory-confirmed negative EtG at each research study visit over the 9-month follow-up period. Additional analyses will evaluate intervention effects on HIV (viral load, and CD4+ levels), and HCV markers of disease progression (FibroScan).Discussion: The proposed trial design and analysis provides an appropriate conceptual and methodological framework to assess the efficacy of the computer-based intervention. We propose to recruit 200 participants. The intervention, if efficacious, may be an efficient and cost-effective alcohol reduction strategy that is scalable and can be readily disseminated and integrated in clinical care in Russia to reduce women’s alcohol consumption and enhance HIV/HCV prognosis.Trial registration: ClinicalTrials.gov, NCT03362476. Registered 5 December 2017, https://clinicaltrials.gov/ct2/show/NCT03362476
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.